Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 11 articles:
HTML format

Single Articles

    June 2020
  1. GUTZMER R, Stroyakovskiy D, Gogas H, Robert C, et al
    Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2020;395:1835-1844.
    PubMed     Abstract available

  2. RIBAS A
    Triple therapy for BRAF(V600)-mutated melanoma.
    Lancet. 2020;395:1814-1815.

    May 2020
  3. ZIMMER L, Livingstone E, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2020;395:1558-1568.
    PubMed     Abstract available

    Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
    Lancet. 2020;395:1524-1525.

    July 2019
  5. THOMPSON JF, Friedman EB
    Appropriate excision margins for cutaneous melanomas.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31272.

  6. UTJES D, Malmstedt J, Teras J, Drzewiecki K, et al
    2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31132.
    PubMed     Abstract available

    March 2019
  7. JANUSZEWICZ W, Corrie P, Liu H, Chan J, et al
    A sinister black finding in the stomach.
    Lancet. 2019;393:1149.

    September 2018
  8. SCHADENDORF D, van Akkooi ACJ, Berking C, Griewank KG, et al
    Lancet. 2018;392:971-984.
    PubMed     Abstract available

    June 2018
  9. LIU XK, Li J
    Acral lentiginous melanoma.
    Lancet. 2018;391:e21.

    August 2017
    KEYNOTE-006: a success in melanoma, but a long way to go.
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31816.

  11. SCHACHTER J, Ribas A, Long GV, Arance A, et al
    Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31601.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.